About Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: NASDAQ:ZYNE
- CUSIP: N/A
- Web: zynerba.com
- Current Ratio: 8.65%
- Quick Ratio: 8.65%
Sales & Book Value:
- Annual Sales: $10,000.00
- Price / Sales: 19,769.45
- Book Value: $4.77 per share
- Price / Book: 3.06
- Trailing EPS: ($2.59)
- Net Income: $-23,380,000.00
- Return on Equity: -50.64%
- Return on Assets: -45.05%
- Employees: 12
- Outstanding Shares: 13,550,000
Frequently Asked Questions for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
What is Zynerba Pharmaceuticals' stock symbol?
Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."
How were Zynerba Pharmaceuticals' earnings last quarter?
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.05. During the same period last year, the business posted ($0.67) earnings per share. View Zynerba Pharmaceuticals' Earnings History.
Where is Zynerba Pharmaceuticals' stock going? Where will Zynerba Pharmaceuticals' stock price be in 2017?
9 analysts have issued 1-year price targets for Zynerba Pharmaceuticals' shares. Their forecasts range from $7.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' stock price to reach $15.13 in the next year. View Analyst Ratings for Zynerba Pharmaceuticals.
What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?
Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (11/18/2017)
- 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
- 3. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)
Are investors shorting Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals saw a increase in short interest during the month of October. As of October 13th, there was short interest totalling 2,836,313 shares, an increase of 27.4% from the September 29th total of 2,227,100 shares. Based on an average trading volume of 797,348 shares, the short-interest ratio is currently 3.6 days. Currently, 26.9% of the company's stock are sold short.
Who are some of Zynerba Pharmaceuticals' key competitors?
Some companies that are related to Zynerba Pharmaceuticals include Celldex Therapeutics (CLDX), Voyager Therapeutics (VYGR), Protagonist Therapeutics (PTGX), Agenus (AGEN), Horizon Discovery Group plc (HZD), Protalix Biotherapeutics (PLX), NewLink Genetics Corporation (NLNK), Arbutus Biopharma Corporation (ABUS), ChromaDex (CDXC), Puretech Health PLC (PRTC), Codexis (CDXS), Cellular Dynamics International (ICEL), GTx (GTXI), CASI Pharmaceuticals (CASI), Nabriva Therapeutics AG (NBRV), Corvus Pharmaceuticals (CRVS), OncoMed Pharmaceuticals (OMED) and Palatin Technologies (PTN).
Who are Zynerba Pharmaceuticals' key executives?
Zynerba Pharmaceuticals' management team includes the folowing people:
- Armando Anido, Chairman of the Board, Chief Executive Officer (Age 59)
- Terri B. Sebree, President (Age 59)
- James E. Fickenscher, Chief Financial Officer, Vice President - Corporate Development (Age 53)
- Suzanne M. Hanlon, Secretary, General Counsel and Vice President, Human Resources (Age 60)
- William Roberts, Vice President - Investor Relations and Corporate Communications
- Ray Mannion, Vice President - Manufacturing
- Brian Rosenberger, Vice President - Commercial (Age 48)
- Warren D. Cooper M.D., Lead Independent Director (Age 64)
- William J. Federici, Independent Director (Age 57)
- Thomas L. Harrison, Independent Director (Age 69)
When did Zynerba Pharmaceuticals IPO?
(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.
Who owns Zynerba Pharmaceuticals stock?
Zynerba Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include RTW Investments LP (1.51%), Granite Point Capital Management L.P. (1.51%), Perceptive Advisors LLC (0.99%), Wells Fargo & Company MN (0.26%), Engineers Gate Manager LP (0.24%) and Rothschild Investment Corp IL (0.21%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.
Who sold Zynerba Pharmaceuticals stock? Who is selling Zynerba Pharmaceuticals stock?
Who bought Zynerba Pharmaceuticals stock? Who is buying Zynerba Pharmaceuticals stock?
Zynerba Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, RTW Investments LP, Granite Point Capital Management L.P., Wells Fargo & Company MN, Engineers Gate Manager LP, Cowen Inc. and Zeke Capital Advisors LLC. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.
How do I buy Zynerba Pharmaceuticals stock?
Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zynerba Pharmaceuticals' stock price today?
One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $14.59.
How big of a company is Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals has a market capitalization of $197.75 million and generates $10,000.00 in revenue each year. The company earns $-23,380,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Zynerba Pharmaceuticals employs 12 workers across the globe.
How can I contact Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals' mailing address is 80 W. Lancaster Avenue, Suite 300, DEVON, PA 19333, United States. The company can be reached via phone at +1-484-5817505 or via email at [email protected]
MarketBeat Community Rating for Zynerba Pharmaceuticals (ZYNE)MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 5 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.44)|
|Consensus Price Target: ||$15.13 (3.67% upside)|
Consensus Price Target History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
(Data available from 11/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/20/2017||Cantor Fitzgerald||Set Price Target||Buy||$17.00||N/A|
|11/14/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Hold||N/A|
|11/14/2017||Piper Jaffray Companies||Boost Price Target||$16.00 -> $20.00||N/A|
|10/1/2017||Roth Capital||Set Price Target||Buy||$15.00||Medium|
|9/29/2017||Canaccord Genuity||Boost Price Target||Buy||$9.00 -> $15.00||High|
|8/15/2017||CIBC||Reiterated Rating||Outperform -> Market Perform||Low|
|8/15/2017||HC Wainwright||Set Price Target||Hold||$7.00||Low|
|8/15/2017||Jefferies Group LLC||Downgrade||Buy -> Hold||$12.00 -> $7.00||Low|
|8/14/2017||Maxim Group||Reiterated Rating||Hold||High|
Earnings History and Estimates Chart for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Earnings History by Quarter for Zynerba Pharmaceuticals (NASDAQ ZYNE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/1/2017||Q2 2017||($0.60)||($0.64)||$0.38 million||View||N/A|
|5/9/2017||Q1 2017||($0.55)||($0.60)||$0.07 million||View||N/A|
|11/14/2016||Q3 2016||($0.69)||($0.67)||$0.20 million||View||N/A|
|5/12/2016||Q1||($0.56)||($0.49)||$0.03 million||$0.01 million||View||N/A|
|3/14/2016||Q415||($0.29)||($0.62)||$0.20 million||$0.05 million||View||N/A|
Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
2017 EPS Consensus Estimate: ($2.27)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Zynerba Pharmaceuticals (NASDAQ ZYNE)
Insider Ownership Percentage: 10.02%
Institutional Ownership Percentage: 23.59%
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ ZYNE)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/23/2017||Michael Rapp||Major Shareholder||Buy||25,745||$9.94||$255,905.30|| |
|10/19/2017||Michael Rapp||Major Shareholder||Buy||44,255||$9.59||$424,405.45|| |
|5/15/2017||Armando Anido||Chairman||Buy||5,000||$19.70||$98,500.00|| |
|5/12/2017||James E Fickenscher||CFO||Buy||5,200||$19.82||$103,064.00|| |
|12/29/2016||Michael Rapp||Major Shareholder||Buy||10,000||$15.85||$158,500.00|| |
|12/7/2016||James E Fickenscher||CFO||Buy||7,000||$14.08||$98,560.00|| |
|8/16/2016||Suzanne M Hanlon||Insider||Sell||3,000||$10.53||$31,590.00|| |
Latest Headlines for Zynerba Pharmaceuticals (NASDAQ ZYNE)
|Cantor Fitzgerald Reiterates "$17.00" Price Target for Zynerba Pharmaceuticals, Inc. (ZYNE)|
www.americanbankingnews.com - November 21 at 8:15 PM
|Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?|
finance.yahoo.com - November 20 at 9:32 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Hold Rating from Oppenheimer Holdings, Inc.|
www.americanbankingnews.com - November 19 at 10:20 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Downgraded by Zacks Investment Research to Sell|
www.americanbankingnews.com - November 18 at 9:44 AM
|FY2017 EPS Estimates for Zynerba Pharmaceuticals, Inc. (ZYNE) Decreased by Oppenheimer Holdings|
www.americanbankingnews.com - November 17 at 7:10 PM
|Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)|
globenewswire.com - November 16 at 11:03 AM
|Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights|
finance.yahoo.com - November 16 at 11:03 AM
|Zynerba reports 3Q loss|
finance.yahoo.com - November 16 at 11:03 AM
|Piper Jaffray Companies Boosts Zynerba Pharmaceuticals, Inc. (ZYNE) Price Target to $20.00|
www.americanbankingnews.com - November 15 at 12:16 AM
|Analyzing Zynerba Pharmaceuticals (ZYNE) & BeyondSpring (BYSI)|
www.americanbankingnews.com - November 14 at 7:40 AM
|Critical Analysis: Zynerba Pharmaceuticals (ZYNE) & OncoSec Medical (ONCS)|
www.americanbankingnews.com - November 11 at 3:28 PM
|Biotech M&A Momentum Attractive for Cannabinoid R&D Space|
www.prnewswire.com - November 7 at 4:23 PM
|Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences|
finance.yahoo.com - November 7 at 4:23 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - November 5 at 1:42 PM
|Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma ... - PR Newswire (press release)|
www.prnewswire.com - October 30 at 8:53 AM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Sees Large Increase in Short Interest|
www.americanbankingnews.com - October 28 at 2:26 AM
|How Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals|
www.marketwatch.com - October 24 at 12:56 PM
|3 Marijuana Stocks That Like to Live Life Dangerously|
finance.yahoo.com - October 24 at 12:56 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Michael Rapp Buys 25,745 Shares|
www.americanbankingnews.com - October 23 at 10:34 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Buys $424,405.45 in Stock|
www.americanbankingnews.com - October 23 at 10:34 PM
|Critical Analysis: Zynerba Pharmaceuticals (ZYNE) and Alnylam Pharmaceuticals (ALNY)|
www.americanbankingnews.com - October 22 at 10:10 AM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - October 18 at 8:58 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Upgraded to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - October 14 at 5:16 PM
|Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week|
finance.yahoo.com - October 12 at 10:37 AM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - October 11 at 4:42 PM
|Benzinga's Top Upgrades, Downgrades For October 2, 2017 - Benzinga|
www.benzinga.com - October 3 at 4:42 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Given a $15.00 Price Target by Roth Capital Analysts|
www.americanbankingnews.com - October 2 at 3:14 PM
|5 Stocks To Watch For September 29, 2017 - Benzinga|
www.benzinga.com - October 1 at 6:44 AM
|Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain|
www.benzinga.com - September 30 at 10:52 AM
|Zynerba's stock on a high as cannabis-based drug succeeds in trial - Reuters|
www.reuters.com - September 29 at 10:37 PM
|Zynerba Pharmaceuticals Reaches Analyst Target Price|
www.thestreet.com - September 29 at 5:35 PM
|BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study|
www.reuters.com - September 29 at 5:35 PM
|Zynerba Stock: Where Is It Headed From Here?|
www.investopedia.com - September 29 at 5:35 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Given "Hold" Rating at Oppenheimer Holdings, Inc.|
www.americanbankingnews.com - September 29 at 5:28 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Rating Reiterated by Cantor Fitzgerald|
www.americanbankingnews.com - September 29 at 4:40 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Price Target Raised to $15.00 at Canaccord Genuity|
www.americanbankingnews.com - September 29 at 10:56 AM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Raised to Overweight at Piper Jaffray Companies|
www.americanbankingnews.com - September 28 at 11:28 PM
|Notable Thursday Option Activity: ZYNE, EPC, RDI|
www.thestreet.com - September 28 at 12:51 PM
|Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome|
globenewswire.com - September 28 at 12:51 PM
|Zynerba Pharma Wins Big on Cannabis Trial|
247wallst.com - September 28 at 12:51 PM
|Zynerba's stock on a high as cannabis-based drug succeeds in trial|
www.reuters.com - September 28 at 12:50 PM
|Short Interest in Zynerba Pharmaceuticals, Inc. (ZYNE) Declines By 25.0%|
www.americanbankingnews.com - September 17 at 1:20 AM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - September 16 at 4:54 PM
|Zynerba Pharmaceuticals (ZYNE) vs. Its Rivals Financial Contrast|
www.americanbankingnews.com - September 14 at 2:22 AM
|Zynerba Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire (press release)|
globenewswire.com - September 6 at 3:19 PM
|Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences|
finance.yahoo.com - September 6 at 3:19 PM
|Nemus Bioscience CEO Talks 'Waves Of Dominance' In The Cannabis Therapeutics Industry - Benzinga|
www.benzinga.com - September 5 at 3:40 PM
|2 Marijuana Stocks That Have Imploded Since August Began|
finance.yahoo.com - August 23 at 2:26 PM
|Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - August 22 at 4:36 PM
|Canaccord Genuity Analysts Give Zynerba Pharmaceuticals, Inc. (ZYNE) a $9.00 Price Target|
www.americanbankingnews.com - August 18 at 3:14 PM
Financials are not available for this stock.
Zynerba Pharmaceuticals (NASDAQ ZYNE) Chart for Wednesday, November, 22, 2017